Akèy › Lukemi miyomonositè kwonik › Massachusetts
Etid klinik pou Lukemi miyomonositè kwonik nan Massachusetts
7 etid pou Lukemi miyomonositè kwonik ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07249346A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- DFCI, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT06950034Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.